Literature DB >> 23774790

Immunological changes in psoriasis patients under long-term treatment with fumaric acid esters: risk of Kaposi sarcoma occurrence?

Sandra Philipp1, Georgios Kokolakis1, Martina Hund2, Ellen Witte3, Katrin Witte3, Stefanie Kunz3, Hans Joachim Roewert2, Wolfram Sterry2, Robert Sabat1.   

Abstract

BACKGROUND: Psoriasis is a chronic skin disorder. The most frequently used systemic anti-psoriatic therapy in Germany is fumaric acid esters (FAE).
OBJECTIVES: We aimed to characterize immunological changes in psoriasis patients under FAE treatment. METHODS AND MATERIALS: Over 200 flow-cytometry analyses of blood from 27 psoriasis patients and histological, molecular, and serological analyses of samples from a patient who developed Kaposi sarcoma (KS) during FAE therapy were performed.
RESULTS: The patients receiving FAE showed decreased CD8+ T cell counts, in particular during the first six months. The CD4+ T cell decline was less pronounced and delayed in time. In a patient with KS, we found a profound CD4 and CD8 lymphocytopenia, as well as a NK cell number reduction, although leukocyte and lymphocyte counts were within the recommended limits. The patient was HIV negative, but positive for HHV8. After cessation of FAE therapy, KS regressed. DISCUSSION: HHV8 infection and iatrogenic T cell reduction, prominently of CD8+ T cells, could have contributed to KS development in this patient. Therefore, we suggest a control of CD4+ and CD8+ T cell counts in addition to the commonly-used differential blood counts in patients with a higher HHV8 prevalence or at high risk of other latent viral infections.

Entities:  

Keywords:  HHV-8; Kaposi sarcoma; T cells; fumaric acid esters; psoriasis

Mesh:

Substances:

Year:  2013        PMID: 23774790     DOI: 10.1684/ejd.2013.2014

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  9 in total

Review 1.  [Systemic treatments for psoriasis and psoriatic arthritis].

Authors:  S Philipp; G Kokolakis; R Sabat
Journal:  Hautarzt       Date:  2016-06       Impact factor: 0.751

2.  Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.

Authors:  A H Cross; L Piccio; E E Longbrake; M J Ramsbottom; C Cantoni; L Ghezzi
Journal:  Mult Scler       Date:  2015-10-12       Impact factor: 6.312

3.  Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate.

Authors:  Moogeh Baharnoori; Jennifer Lyons; Akram Dastagir; Igor Koralnik; James M Stankiewicz
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-08-23

4.  Hidden Pictures of Kaposi's Sarcoma in Psoriatic Lesions: A Diagnostic Challenge.

Authors:  Jisook Yoo; Mingyul Jo; Min-Soo Kim; Kwang-Hyun Choi; Hyang-Joon Park; Mihn-Sook Jue
Journal:  Ann Dermatol       Date:  2016-11-23       Impact factor: 1.444

5.  Lymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.

Authors:  C Chaves; R Ganguly; C Ceresia; A Camac
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-04-05

6.  Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.

Authors:  H Dickel; T Bruckner; P Altmeyer
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-18       Impact factor: 6.166

Review 7.  Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.

Authors:  Renaud A Du Pasquier; Daniel D Pinschewer; Doron Merkler
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

Review 8.  Fumaric acid esters in the management of psoriasis.

Authors:  Deepak Mw Balak
Journal:  Psoriasis (Auckl)       Date:  2015-01-05

Review 9.  [What's new in clinical dermatology?].

Authors:  M Janier
Journal:  Ann Dermatol Venereol       Date:  2013-11       Impact factor: 0.777

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.